ArticleAntimicrobial agents and chemotherapy2026
Phage-first treatment results in subpopulation-driven collateral sensitivity to beta-lactams in an extensively drug-resistant
Claire Han, Karishma Patel, Haoran Gao, Jacob T Sanborn, Thomas D Nguyen, Jack F Klem, Brian M Ho, Patrick D Kenney, Yanan Zhao, Troy D Wood and 3 more
Abstract read
In one paragraphArticle in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Claire Han *Division of Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
Karishma Patel *Division of Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
Haoran GaoDivision of Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
Jacob T SanbornDivision of Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
Thomas D NguyenDivision of Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.ORCID 0009-0000-1069-1720 Jack F KlemDivision of Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
Brian M HoDivision of Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.ORCID 0009-0006-9229-4131 Patrick D KenneyDepartment of Infectious Diseases, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.ORCID 0000-0003-0410-5224 Yanan ZhaoDivision of Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
Troy D WoodDepartment of Chemistry, College of Arts and Sciences, University at Buffalo, Buffalo, New York, USA.ORCID 0000-0002-2556-8511 Liang ChenDivision of Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.ORCID 0000-0001-5845-2235 Nicholas M SmithDivision of Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.ORCID 0000-0002-0212-2787 Funding
Pharmacokinetics and Pharmacodynamics of Mechanistically Aware Phage CocktailsR01AI177997 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Nicholas Michael Smith · 2024 to 2026
$2.2MAerosol delivery of combinational therapeutics targeting deadly lung infectionsR01HL167828 · NHLBI · PURDUE UNIVERSITY · PI QI ZHOU · 2024 to 2026
$1.8MNational Institute of Allergy and Infectious Diseases R01AI177997, R01AI165997, R01AI148560NHLBI NIH HHS R01HL167828NIAID NIH HHS L30 AI164450NIAID NIH HHS L30 AI194397NIAID NIH HHS R01 AI177997NIA NIH HHS R01AG056939
6 · The paper itselfAbstract
Indexed as
Anti-Bacterial AgentsBacteriophagesbeta-LactamsPseudomonas aeruginosaPseudomonas PhagesAzabicyclo CompoundsAztreonambeta Lactam AntibioticsDrug Resistance, Multiple, BacterialLipopolysaccharidesMicrobial Sensitivity TestsPseudomonas InfectionsAnti-Bacterial AgentsavibactamAzabicyclo CompoundsAztreonambeta Lactam Antibioticsbeta-LactamsLipopolysaccharidesbacteriophagebeta-lactamcarbapenemcombination therapyKPCLPSpermeabilitypharmacodynamicsPseudomonas aeruginosa
Identifiers
PMID42690188
PMCPMC13689456
What OpenQuestion holds
Textmetadata
Read underepoch 390